U.S. Markets closed

TetraLogic Pharmaceuticals Corporation (TLOG)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.00840.0000 (0.00%)
At close: 1:55PM EDT

TetraLogic Pharmaceuticals Corporation

343 Phoenixville Pike
Malvern, PA 19355
United States
610-889-9900
http://www.tetralogicpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees29

Key Executives

NameTitlePayExercisedYear Born
Dr. Yigong ShiCo-FounderN/AN/A1968
Sarah E. FrewDirector of Bus. & Commercial Devel.N/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to apoptosis or cell-death in damaged cells. SHAPE is its proprietary histone deacetylase inhibitor for topical use for the treatment of early-stage cutaneous T-cell lymphoma. TetraLogic Pharmaceuticals Corporation has research collaboration with Walter and Eliza Hall Institute of Medical Research to examine SMAC-mimetics, including birinapant in the treatment of infectious disease. The company was formerly known as Gentara Corporation and changed its name to TetraLogic Pharmaceuticals Corporation in January 2006. TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Corporate Governance

TetraLogic Pharmaceuticals Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.